Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$3.39 billion
P/E Ratio
267.68
Dividend Yield
0.00%
Shares Outstanding
334.72 million
Earnings per share
0.023
Dividend per share
N/A
Year To Date Return
-10.71%
Earnings Yield
0.37%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals Ltd (ASX: TLX)
Latest News
Broker Notes
2 ASX shares experts think will smash the market in 2026!
Growth Shares
10 ASX shares I would buy in 2026
Growth Shares
In 2036, you will be glad you bought these ASX shares today
Share Market News
These are the 10 most shorted ASX shares
Value Investing
2 ASX 200 shares down 30% or more that could be a new years buy
Healthcare Shares
Telix shares storm higher on big US and China news
Share Market News
These are the 10 most shorted ASX shares
Share Market News
Telix Pharmaceuticals in focus with China trial success and FDA updates
Healthcare Shares
Bell Potter names the best ASX healthcare shares to buy in 2026
Healthcare Shares
Why is everyone talking about Telix shares this week?
Opinions
5 ASX shares I'd buy with $10,000 this week
Healthcare Shares
Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
TLX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 27 Feb 2026 | $10.00 | $-0.20 | -1.96% | 2,747,361 | $10.20 | $10.35 | $9.90 |
| 26 Feb 2026 | $10.20 | $1.00 | 10.87% | 3,379,461 | $9.30 | $10.22 | $9.21 |
| 25 Feb 2026 | $9.20 | $0.17 | 1.88% | 1,976,919 | $9.22 | $9.29 | $9.03 |
| 24 Feb 2026 | $9.03 | $-0.58 | -6.04% | 3,393,303 | $9.70 | $9.88 | $9.00 |
| 23 Feb 2026 | $9.61 | $-0.82 | -7.86% | 4,272,395 | $10.85 | $10.89 | $9.51 |
| 20 Feb 2026 | $10.43 | $1.30 | 14.24% | 7,120,082 | $9.96 | $10.78 | $9.49 |
| 19 Feb 2026 | $9.13 | $0.25 | 2.82% | 4,121,726 | $8.91 | $9.13 | $8.82 |
| 18 Feb 2026 | $8.88 | $0.04 | 0.45% | 2,225,222 | $9.05 | $9.25 | $8.83 |
| 17 Feb 2026 | $8.84 | $0.21 | 2.43% | 3,867,207 | $8.51 | $8.86 | $8.26 |
| 16 Feb 2026 | $8.63 | $-0.13 | -1.48% | 2,345,498 | $8.88 | $9.03 | $8.56 |
| 13 Feb 2026 | $8.76 | $-0.32 | -3.52% | 3,334,991 | $9.08 | $9.23 | $8.76 |
| 12 Feb 2026 | $9.08 | $-0.67 | -6.87% | 3,265,810 | $9.59 | $9.59 | $9.05 |
| 11 Feb 2026 | $9.75 | $-0.31 | -3.08% | 2,094,567 | $10.08 | $10.08 | $9.67 |
| 10 Feb 2026 | $10.06 | $0.20 | 2.03% | 2,274,148 | $9.88 | $10.15 | $9.72 |
| 09 Feb 2026 | $9.86 | $0.01 | 0.10% | 2,693,647 | $10.08 | $10.13 | $9.65 |
| 06 Feb 2026 | $9.85 | $-0.28 | -2.76% | 3,002,322 | $10.00 | $10.00 | $9.59 |
| 05 Feb 2026 | $10.13 | $0.01 | 0.10% | 2,110,210 | $10.24 | $10.46 | $10.09 |
| 04 Feb 2026 | $10.12 | $-0.09 | -0.88% | 3,050,480 | $10.20 | $10.29 | $9.88 |
| 03 Feb 2026 | $10.21 | $-0.27 | -2.58% | 3,802,507 | $10.60 | $10.61 | $10.03 |
| 02 Feb 2026 | $10.48 | $-0.07 | -0.66% | 1,792,171 | $10.55 | $10.66 | $10.28 |
| 30 Jan 2026 | $10.55 | $-0.53 | -4.78% | 3,195,469 | $11.09 | $11.10 | $10.53 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Nov 2025 | Christian Behrenbruch | Exercise | 100,708 | $441,101 |
Exercise of options. Cash consideration
|
| 05 Nov 2025 | Christian Behrenbruch | Issued | 100,708 | $441,101 |
Exercise of options. Cash consideration
|
| 13 Jun 2025 | Christian Behrenbruch | Issued | 169,078 | $1,876,796 |
Director remuneration. Non-cash consideration, Black Scholes valuation, 526,497 Rights
|
| 06 Mar 2025 | Christian Behrenbruch | Expiry | 46,558 | $1,306,417 |
As advised by the company. Lapsed, 3,57,419 Rights
|
| 05 Mar 2025 | Marie McDonald | Buy | 3,719 | $100,078 |
On-market trade. Average price
|
| 05 Mar 2025 | Tiffany Olson | Buy | 11,315 | $319,422 |
On-market trade. Average price
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Jann E Skinner | Non-Executive Director | Jun 2018 |
Ms Skinner was a partner at PricewaterhouseCoopers from 1987 to 2004. She has served as Chair of Create Foundation Limited since July 2024 and Director since 2004. She also served as Non-Executive Director of QBE Insurance Group Limited from October 2014 to May 2024 and Director of HSBC Bank Australia Limited from April 2017 to April 2023. She is Chair of Risk Committee and member of people committee.
|
| Ms Marie Elizabeth McDonald | Non-Executive Director | Mar 2025 |
Ms McDonald serves as a Non-Executive Director of Nanosonics Limited (since October 2016), Walter and Eliza Hall Institute of Medical Research (since October 2016) and Nufarm Limited (since March 2017) and served as a Non-Executive Director of CSL Limited between August 2013 and October 2025. She is member of the Risk Committee and Chair of People Committee.
|
| Dr Christian Peter Behrenbruch | Chief Executive OfficerManaging Director | Jan 2017 |
Dr Behrenbruch has previously served as Chief Executive Officer at Mirada Solutions from July 2001 to December 2002, President at CTI Molecular Imaging (now Siemens Healthcare) from August 2003 to September 2006, Chief Executive Officer at Fibron Technologies, Inc. from June 2008 to December 2011 and Chief Executive Officer at ImaginAb, Inc from October 2007 to February 2015.
|
| Dr Mark Alexander Nelson | Non-Executive DirectorInterim Chairman | Sep 2017 |
Dr Nelson has served as Chairman of the Caledonia Investments Group since January 2012, and as a Director of The Caledonia Foundation since August 2002. He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group from February 1992 to January 2012. He has also served as Director of Kaldor Public Art Projects since October 2005, Governor of the Florey Neurosciences Institute since October 2007, Director of the Mindgardens Neuroscience Network since February 2018 and Chairman of Art Exhibitions Australia since 2019. He is member of Risk Committee and People Committee.
|
| Ms Genevieve Ryan | Company Secretary | Dec 2022 |
-
|
| Raphael Ortiz | Chief Executive Officer Telix International |
-
|
|
| Kevin Richardson | Chief Executive Officer Telix Precision Medicine |
-
|
|
| Richard Valeix | Chief Executive Officer Telix Therapeutics |
-
|
|
| Genevieve Ryan | Company Secretary |
-
|
|
| Darren Smith | Group Chief Financial Officer |
-
|
|
| David Cade | Group Chief Medical Officer |
-
|
|
| Mary Jessel | Group Chief of Clinical Affairs |
-
|
|
| Darren Patti | Group Chief Operating Officer |
-
|
|
| Lena Moran-Adams | Group General Counsel |
-
|
|
| Meredith Crowe | Senior Vice President People & Culture |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 53,462,930 | 15.80% |
| Citicorp Nominees Pty Limited | 31,693,330 | 9.40% |
| J P Morgan Nominees Australia Pty Limited | 24,921,869 | 7.40% |
| ELK River Holdings Pty Ltd | 20,675,000 | 6.10% |
| Gnosis Verwaltungsgesellschaft Mbh | 20,675,000 | 6.10% |
| BNP Paribas Nominees Pty Ltd | 15,376,442 | 4.50% |
| BNP Paribas Noms Pty Ltd | 10,433,812 | 3.10% |
| Grand Decade Developments Limited | 6,000,000 | 1.80% |
| BNP Paribas Nominees Pty Ltd i | 5,643,043 | 1.70% |
| UV Cap Gmbh and Co Kg | 4,878,261 | 1.40% |
| Merrill Lynch (Australia) Nominees Pty Limited | 3,294,701 | 1.00% |
| Man Holdings Pty Ltd | 3,228,750 | 1.00% |
| BNP Paribas Nominees Pty Ltd ii | 2,923,857 | 0.90% |
| BNP Paribas Noms (Nz) Ltd | 2,714,023 | 0.80% |
| Netwealth Investments Limited | 2,406,576 | 0.70% |
| Lightpoint Medical Ltd | 1,918,112 | 0.60% |
| The Oncidium Foundation | 1,846,582 | 0.60% |
| Pacific Custodians Pty Limited | 1,618,200 | 0.50% |
| Ubs Nominees Pty Ltd | 1,191,214 | 0.40% |
| WHSP Holdings Pty Limited | 1,136,783 | 0.30% |
| BNP Paribas Nominees Pty Ltd iii | 1,120,510 | 0.30% |
